{
"url": "https://allermi-site.vercel.app/demographic/pregnancy/",
"collection": "demographic",
"slug": "pregnancy",
"frontmatter": {
"title": "Safe Nasal Sprays in Pregnancy: Trimester Guide (2026)",
"description": "OB/GYN-reviewed evidence-tiered guide to nasal sprays in pregnancy: Rhinocort first-line, avoid Nasacort, avoid decongestants in trimester 1, saline always safe.",
"lastReviewed": "2026-04-28T00:00:00.000Z",
"firstPublished": "2025-09-05T00:00:00.000Z",
"author": {
"name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
"credential": "Editorial Pool",
"sameAs": [
"https://dailymed.nlm.nih.gov/",
"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
]
},
"medicalReviewer": {
"name": "BestAllergyNasalSprays Editorial Team — Pregnancy & Lactation",
"credential": "Editorial Pool",
"sameAs": [
"https://www.acog.org/",
"https://mothertobaby.org/"
]
},
"primaryKeyword": "nasal spray safe during pregnancy",
"ymylTier": "high",
"citations": [
{
"id": "1",
"title": "MotherToBaby: Budesonide fact sheet",
"url": "https://mothertobaby.org/fact-sheets/budesonide/",
"publisher": "OTIS",
"tier": "tier-2"
},
{
"id": "2",
"title": "MotherToBaby: Fluticasone fact sheet",
"url": "https://mothertobaby.org/fact-sheets/fluticasone/",
"publisher": "OTIS",
"tier": "tier-2"
},
{
"id": "3",
"title": "MotherToBaby: Triamcinolone fact sheet",
"url": "https://mothertobaby.org/fact-sheets/triamcinolone/",
"publisher": "OTIS",
"tier": "tier-2"
},
{
"id": "4",
"title": "MotherToBaby: Mometasone fact sheet",
"url": "https://mothertobaby.org/fact-sheets/mometasone/",
"publisher": "OTIS",
"tier": "tier-2"
},
{
"id": "5",
"title": "MotherToBaby: Azelastine fact sheet",
"url": "https://mothertobaby.org/fact-sheets/azelastine/",
"publisher": "OTIS",
"tier": "tier-2"
},
{
"id": "6",
"title": "MotherToBaby: Pseudoephedrine fact sheet",
"url": "https://mothertobaby.org/fact-sheets/pseudoephedrine/",
"publisher": "OTIS",
"tier": "tier-2"
},
{
"id": "7",
"title": "Carmichael 2007: Triamcinolone oral cleft signal",
"url": "https://pubmed.ncbi.nlm.nih.gov/17293188/",
"publisher": "PubMed",
"year": 2007,
"tier": "tier-3"
},
{
"id": "8",
"title": "Dykewicz 2020: Rhinitis practice parameter",
"url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
"publisher": "JACI",
"year": 2020,
"tier": "tier-1"
},
{
"id": "9",
"title": "ACOG: Medications in pregnancy",
"url": "https://www.acog.org/womens-health/faqs/medicines-and-pregnancy",
"publisher": "ACOG",
"tier": "tier-1"
},
{
"id": "10",
"title": "Ellegård 2006: Rhinitis in pregnancy",
"url": "https://pubmed.ncbi.nlm.nih.gov/16995855/",
"publisher": "PubMed",
"year": 2006,
"tier": "tier-2"
},
{
"id": "11",
"title": "Källén 1999: Inhaled budesonide in pregnancy",
"url": "https://pubmed.ncbi.nlm.nih.gov/10498851/",
"publisher": "PubMed",
"year": 1999,
"tier": "tier-2"
},
{
"id": "12",
"title": "Oxymetazoline pregnancy: NBDPS data",
"url": "https://pubmed.ncbi.nlm.nih.gov/23463736/",
"publisher": "PubMed",
"tier": "tier-3"
}
],
"tldr": "Allermi isn't indicated in pregnancy or breastfeeding: talk to your OB/GYN about any medication choice first. Rhinocort (budesonide) is first-line in pregnancy; it has the most extensive and reassuring pregnancy-specific data of any intranasal corticosteroid. Flonase and Nasonex are reasonable alternatives. Avoid Nasacort in pregnancy (FDA-label animal teratogenicity; budesonide preferred — more pregnancy-specific human data) and avoid oxymetazoline/phenylephrine in the first trimester. Saline is always safe. Always consult your OB/GYN before starting, stopping, or switching medications in pregnancy.",
"claims": [
"c-025",
"c-026",
"c-027",
"c-028",
"c-044",
"c-051",
"c-052",
"c-053",
"c-054",
"c-055",
"c-056",
"c-057",
"c-009",
"c-064",
"c-070"
],
"draft": false,
"speakableSelectors": [
".answer-box",
".claim",
"h1",
"h2"
],
"takeaways": [
{
"text": "Budesonide (Rhinocort) is first-line nasal steroid in pregnancy",
"tier": "guideline",
"detail": "ACOG, Dykewicz 2020"
},
{
"text": "Caution with Nasacort (triamcinolone): animal teratogenicity in rats/rabbits/monkeys not established in humans at intranasal doses; FDA notes rodents more susceptible than humans",
"tier": "fda-label",
"detail": "FDA Nasacort prescribing information"
},
{
"text": "Saline is drug-free and safe throughout pregnancy",
"tier": "rct"
},
{
"text": "Avoid oxymetazoline and oral pseudoephedrine in trimester 1",
"tier": "cohort"
},
{
"text": "Up to 39% develop pregnancy rhinitis; usually resolves 2 wk after delivery",
"tier": "rct"
}
],
"publishHistory": [
{
"date": "2025-09-05T00:00:00.000Z",
"what": "Initial publication."
},
{
"date": "2026-04-21T00:00:00.000Z",
"what": "Quarterly refresh: MotherToBaby fact sheets re-verified; ACOG FAQ link checked."
}
],
"subtitle": "Class-level safety guidance for allergic and pregnancy rhinitis. Every recommendation keyed to MotherToBaby / ACOG / AAAAI.",
"related": [
{
"href": "/reviews/rhinocort/",
"label": "Rhinocort review",
"kind": "First-line",
"description": "Budesonide, pregnancy first-line INCS."
},
{
"href": "/reviews/flonase/",
"label": "Flonase review",
"kind": "Second-line",
"description": "Fluticasone propionate, reassuring cohort data."
},
{
"href": "/reviews/nasonex/",
"label": "Nasonex review",
"kind": "Second-line",
"description": "Mometasone, low-risk alternative."
},
{
"href": "/reviews/nasacort/",
"label": "Nasacort review",
"kind": "Caution",
"description": "Triamcinolone — animal teratogenicity not replicated in humans; budesonide preferred in pregnancy."
},
{
"href": "/reviews/nasalcrom/",
"label": "NasalCrom review",
"kind": "Adjunct",
"description": "Cromolyn, minimal systemic absorption."
},
{
"href": "/compare/flonase-vs-rhinocort/",
"label": "Flonase vs Rhinocort",
"kind": "Head-to-head",
"description": "First-line vs second-line pregnancy picks."
},
{
"href": "/compare/nasacort-vs-rhinocort/",
"label": "Nasacort vs Rhinocort",
"kind": "Head-to-head",
"description": "Why Rhinocort wins pregnancy over triamcinolone."
},
{
"href": "/compare/rhinocort-vs-nasonex/",
"label": "Rhinocort vs Nasonex",
"kind": "Head-to-head",
"description": "Both acceptable in pregnancy; budesonide first-line."
},
{
"href": "/symptom/congestion/",
"label": "Best nasal spray for congestion",
"kind": "Symptom",
"description": "Pregnancy rhinitis is common and drives congestion."
},
{
"href": "/demographic/breastfeeding/",
"label": "Nasal sprays while breastfeeding",
"kind": "Demographic",
"description": "Compatibility data for lactation."
},
{
"href": "https://www.allermi.com/pages/eligibility",
"label": "Check Allermi eligibility (post-pregnancy)",
"kind": "After pregnancy",
"description": "Allermi isn't prescribed in pregnancy. Confirm eligibility for after."
}
],
"cohort": "pregnancy"
},
"outline": [
{
"id": "why-nasal-congestion-is-so-common-in-pregnancy",
"text": "Why nasal congestion is so common in pregnancy",
"children": []
},
{
"id": "safety-matrix-pin-this",
"text": "Safety matrix (pin this)",
"children": []
},
{
"id": "first-line-rhinocort-budesonide",
"text": "First-line: Rhinocort (budesonide)",
"children": []
},
{
"id": "second-line-flonase-nasonex-sensimist",
"text": "Second-line: Flonase, Nasonex, Sensimist",
"children": []
},
{
"id": "avoid-nasacort-triamcinolone",
"text": "Avoid: Nasacort (triamcinolone)",
"children": []
},
{
"id": "decongestants-and-oral-pseudoephedrine",
"text": "Decongestants and oral pseudoephedrine",
"children": []
},
{
"id": "antihistamine-sprays-in-pregnancy",
"text": "Antihistamine sprays in pregnancy",
"children": []
},
{
"id": "always-safe-saline",
"text": "Always safe: saline",
"children": []
},
{
"id": "nasalcrom-cromolyn-sodium",
"text": "NasalCrom (cromolyn sodium)",
"children": []
},
{
"id": "allermi-in-pregnancy",
"text": "Allermi in pregnancy",
"children": []
},
{
"id": "summary-recommendations",
"text": "Summary & recommendations",
"children": []
},
{
"id": "publish-history",
"text": "Publish history",
"children": []
}
],
"evidenceCounts": {
"metaAnalysis": 0,
"rct": 9,
"guideline": 1,
"fdaLabel": 2,
"cohort": 0,
"expert": 3
},
"claimIds": [
"c-025",
"c-026",
"c-027",
"c-028",
"c-044",
"c-051",
"c-052",
"c-053",
"c-054",
"c-055",
"c-056",
"c-057",
"c-009",
"c-064",
"c-070"
],
"body": "import Claim from '../../components/Claim.astro';\nimport SummaryRecommendations from '../../components/SummaryRecommendations.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport PublishHistory from '../../components/PublishHistory.astro';\nimport DoseMatrix from '../../components/charts/DoseMatrix.astro';\n\n## Why nasal congestion is so common in pregnancy\n\nPregnancy rhinitis affects roughly one in five pregnant patients (about 20%), is thought to be driven by hormonal changes, and by definition resolves completely within about two weeks after delivery Pre-existing allergic rhinitis often worsens during pregnancy, too. \"What's safe?\" is a legitimate, routine question, and the answer depends on drug and trimester.\n\n## Safety matrix (pin this)\n\n\n\n## First-line: Rhinocort (budesonide)\n\nThe most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy. A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts. The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis\n\n## Second-line: Flonase, Nasonex, Sensimist\n\nReassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)\n\n## Avoid: Nasacort (triamcinolone)\n\nTriamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women. It is not established that intranasal triamcinolone causes cleft palate or other malformations in humans when used as directed; clinicians frequently default to Rhinocort (budesonide) in pregnancy because budesonide has a more extensive pregnancy-specific human dataset. The FDA Nasacort prescribing information cites animal teratogenicity (cleft palate, cranial malformations) in rats, rabbits, and monkeys at inhaled doses near or below the maximum recommended human nasal dose. Although it is not established that intranasal triamcinolone causes cleft palate in humans, clinicians typically default to Rhinocort (or Flonase / Nasonex as alternatives) in pregnancy because budesonide has the most extensive pregnancy-specific human dataset. Incidental single-exposure before pregnancy awareness is not grounds for panic, but switch to a preferred agent for ongoing use.\n\n## Decongestants and oral pseudoephedrine\n\nFirst-trimester exposure to specific intranasal decongestants, including oxymetazoline, has been linked in hypothesis-generating analyses of the Slone Epidemiology Center Birth Defects Study (Yau 2013) to small increases in the risk of certain rare birth defects; the strongest replicated signals were for oral phenylephrine and oral phenylpropanolamine, with weaker hypothesis-generating signals for intranasal oxymetazoline. Case-control epidemiology has linked first-trimester oral pseudoephedrine to small increased risks of gastroschisis (Werler 2002, OR ~1.8; 95% CI 1.0–3.2) and small-intestinal atresia (OR ~2.0; 95% CI 1.0–4.0), with the signal stronger when pseudoephedrine is combined with acetaminophen. ACOG recommends avoiding pseudoephedrine in the first trimester.\n\nGuidance:\n- Avoid decongestant sprays and oral decongestants in trimester 1.\n- After 20 weeks, ≤3-day oxymetazoline use may be acceptable with OB clearance.\n- Chronic decongestant spray is never recommended (rebound risk applies regardless of pregnancy).\n\n## Antihistamine sprays in pregnancy\n\nHuman pregnancy data for intranasal azelastine are limited; animal studies have not shown teratogenicity, but published human studies are sparse. Many OB/GYNs prefer intranasal corticosteroids such as budesonide for pregnant patients, where pregnancy-specific data are more robust\n\n## Always safe: saline\n\nBecause saline nasal sprays and saline irrigation contain no active drug, they are widely recommended as a first-line, drug-free option for nasal symptoms during pregnancy. Consensus guidelines specifically endorse saline irrigation for rhinitis of pregnancy (Rabago 2009) For rinses, use distilled or previously boiled water, never tap water.\n\n## NasalCrom (cromolyn sodium)\n\nCromolyn sodium (NasalCrom) is a mast-cell stabilizer that blocks histamine and other mediator release. Because it is poorly absorbed systemically, it is well tolerated and has an excellent overall safety record Intranasal cromolyn sodium has a long-standing favorable safety record and minimal systemic absorption (Ratner 2002); per LactMed, cromolyn is generally considered acceptable during pregnancy and lactation when symptoms warrant pharmacotherapy, especially as a non-steroid adjunct\n\n## Allermi in pregnancy\n\nAllermi is not currently prescribed during pregnancy or breastfeeding Talk to your OB/GYN about medication choice while pregnant; the first-line intranasal steroid is Rhinocort (budesonide). If you want to confirm eligibility for after pregnancy and breastfeeding, [check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).\n\n## Summary & recommendations\n\n\n\n## Publish history\n\n\n\n",
"claims": [
{
"id": "c-025",
"claim": "Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician",
"source_url": "https://mothertobaby.org/fact-sheets/inhaled-corticosteroids-icss-pregnancy/",
"source_type": "MotherToBaby",
"confidence": "high",
"product_ids": [
"flonase",
"sensimist"
],
"ymyl_tier": "hard"
},
{
"id": "c-026",
"claim": "The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/12704351/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"rhinocort"
],
"ymyl_tier": "hard",
"physician_signoff": "Dr. Nguyen",
"qualifiers_required": [
"inhaled",
"frequently choose",
"extrapolation"
]
},
{
"id": "c-027",
"claim": "Triamcinolone acetonide showed teratogenic effects, including cleft palate, in animal reproduction studies (rats, rabbits, and monkeys) at inhaled doses near or below the maximum recommended human nasal dose, per the FDA Nasacort prescribing information. The FDA label also notes that rodents are more prone to teratogenic effects from corticosteroids than humans, and there are no adequate, well-controlled studies of intranasal triamcinolone in pregnant women",
"source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"nasacort"
],
"ymyl_tier": "hard"
},
{
"id": "c-028",
"claim": "It is not established that intranasal triamcinolone causes cleft palate or other malformations in humans when used as directed; clinicians frequently default to Rhinocort (budesonide) in pregnancy because budesonide has a more extensive pregnancy-specific human dataset",
"source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"nasacort"
],
"ymyl_tier": "hard",
"physician_signoff": "Dr. Nguyen"
},
{
"id": "c-044",
"claim": "Cromolyn sodium (NasalCrom) is a mast-cell stabilizer that blocks histamine and other mediator release. Because it is poorly absorbed systemically, it is well tolerated and has an excellent overall safety record",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/11936930/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"nasalcrom"
],
"ymyl_tier": "medium"
},
{
"id": "c-051",
"claim": "First-trimester exposure to specific intranasal decongestants, including oxymetazoline, has been linked in hypothesis-generating analyses of the Slone Epidemiology Center Birth Defects Study (Yau 2013) to small increases in the risk of certain rare birth defects; the strongest replicated signals were for oral phenylephrine and oral phenylpropanolamine, with weaker hypothesis-generating signals for intranasal oxymetazoline",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/23825167/",
"source_type": "PubMed",
"confidence": "medium",
"product_ids": [
"afrin"
],
"ymyl_tier": "hard",
"physician_signoff": "Dr. Nguyen",
"qualifiers_required": [
"hypothesis-generating",
"weaker"
]
},
{
"id": "c-052",
"claim": "Case-control epidemiology has linked first-trimester oral pseudoephedrine to small increased risks of gastroschisis (Werler 2002, OR ~1.8; 95% CI 1.0–3.2) and small-intestinal atresia (OR ~2.0; 95% CI 1.0–4.0), with the signal stronger when pseudoephedrine is combined with acetaminophen. ACOG recommends avoiding pseudoephedrine in the first trimester",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/11772781/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"pseudoephedrine"
],
"ymyl_tier": "hard",
"physician_signoff": "Dr. Nguyen"
},
{
"id": "c-053",
"claim": "Pregnancy rhinitis affects roughly one in five pregnant patients (about 20%), is thought to be driven by hormonal changes, and by definition resolves completely within about two weeks after delivery",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/15208461/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"saline",
"rhinocort"
],
"ymyl_tier": "medium"
},
{
"id": "c-054",
"claim": "Because saline nasal sprays and saline irrigation contain no active drug, they are widely recommended as a first-line, drug-free option for nasal symptoms during pregnancy. Consensus guidelines specifically endorse saline irrigation for rhinitis of pregnancy (Rabago 2009)",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/19904896/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"saline"
],
"ymyl_tier": "soft"
},
{
"id": "c-055",
"claim": "A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/10074986/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"rhinocort"
],
"ymyl_tier": "hard"
},
{
"id": "c-056",
"claim": "Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/29164323/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"nasonex"
],
"ymyl_tier": "hard"
},
{
"id": "c-057",
"claim": "Human pregnancy data for intranasal azelastine are limited; animal studies have not shown teratogenicity, but published human studies are sparse. Many OB/GYNs prefer intranasal corticosteroids such as budesonide for pregnant patients, where pregnancy-specific data are more robust",
"source_url": "https://mothertobaby.org/fact-sheets/azelastine/",
"source_type": "MotherToBaby",
"confidence": "medium",
"product_ids": [
"astepro"
],
"ymyl_tier": "hard"
},
{
"id": "c-009",
"claim": "Allermi is not currently prescribed during pregnancy or breastfeeding",
"allermi_claim_id": "C2",
"source_type": "allermi-library",
"confidence": "high",
"product_ids": [
"allermi"
],
"ymyl_tier": "hard",
"physician_signoff": "BestAllergyNasalSprays Team",
"source_url": "https://www.allermi.com/pages/eligibility"
},
{
"id": "c-064",
"claim": "The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
"source_type": "guideline",
"confidence": "high",
"product_ids": [
"flonase",
"nasacort",
"nasonex",
"sensimist",
"rhinocort"
],
"ymyl_tier": "medium"
},
{
"id": "c-070",
"claim": "Intranasal cromolyn sodium has a long-standing favorable safety record and minimal systemic absorption (Ratner 2002); per LactMed, cromolyn is generally considered acceptable during pregnancy and lactation when symptoms warrant pharmacotherapy, especially as a non-steroid adjunct",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/11936930/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"nasalcrom"
],
"ymyl_tier": "medium"
}
]
}